Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus RIVIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus RIVIVE.
ADLARITY vs RIVIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Selective serotonin reuptake inhibitor (SSRI). Increases extracellular levels of serotonin by inhibiting its reuptake into presynaptic neurons, enhancing serotonergic neurotransmission.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Intravenous infusion of 500 mg over 60 minutes every 12 hours for 14 days.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
The terminal elimination half-life is approximately 24-30 hours in healthy adults, allowing for once-daily dosing. In patients with hepatic impairment, half-life may be prolonged, requiring dose adjustment.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
RIVIVE is primarily eliminated via hepatic metabolism, with approximately 70% of the dose excreted in feces as metabolites and 30% in urine as unchanged drug and metabolites. Renal excretion of unchanged drug accounts for less than 5%.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor